First Bank & Trust Buys 10,881 Shares of Medtronic PLC $MDT

Key Points

• First Bank & Trust increased its Medtronic stake by 43.6% in the third quarter, buying 10,881 shares to bring its holdings to 35,848 shares valued at approximately $3.09 million. Institutional investors collectively own 82.06% of the company.
• Medtronic reported quarterly revenue of $9.76 billion and earnings of $1.45 per share, exceeding analyst expectations, while revenue grew 13.7% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $102.88, compared with the stock’s reported price of $94.79.
• Insiders sold shares worth roughly $5.89 million over the past 90 days under pre-arranged trading plans, while Medtronic continues paying a quarterly dividend of $0.72, equivalent to a 3.0% annualized yield.

First Bank & Trust lifted its stake in shares of Medtronic PLC (NYSE:MDT - Free Report) by 43.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,848 shares of the medical technology company's stock after purchasing an additional 10,881 shares during the quarter. First Bank & Trust's holdings in Medtronic were worth $3,093,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Activest Wealth Management increased its holdings in Medtronic by 470.9% during the 3rd quarter. Activest Wealth Management now owns 314 shares of the medical technology company's stock worth $27,000 after acquiring an additional 259 shares during the period. IAG Wealth Partners LLC purchased a new position in shares of Medtronic during the 2nd quarter valued at $30,000. Pin Oak Investment Advisors Inc. purchased a new position in shares of Medtronic during the 2nd quarter valued at $32,000. Global Assets Advisory LLC purchased a new position in shares of Medtronic during the 1st quarter valued at $36,000. Finally, Core Capital Management & Research inc. bought a new position in shares of Medtronic in the second quarter worth $33,000. Hedge funds and other institutional investors own 82.06% of the company's stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s 2026 Best Inventions list. The recognition supports the company’s innovation strategy and could improve visibility for its surgical and monitoring businesses. Medtronic Named to TIME Best Inventions of 2026
• Positive Sentiment: Medtronic continues expanding in cardiac ablation, robotics, hypertension and digital surgery. Recent sales and profit growth, along with a raised fiscal outlook, provide support for the longer-term investment case. Is Medtronic Stock a Buy Now That Sales Growth Has Picked Up?
• Neutral Sentiment: Medtronic completed the separation of MiniMed, exchanging its remaining shares and leaving the diabetes-technology company fully independent. The transaction simplifies MDT’s portfolio and may allow greater focus on higher-growth medical-device businesses, but it also removes direct ownership of MiniMed and changes the company’s revenue mix. Medtronic Completes Separation of MiniMed Group
• Negative Sentiment: Analyst sentiment remains cautious: Piper Sandler assigned a Hold rating, while Barclays began coverage at Equal Weight. These ratings suggest limited near-term upside after MDT’s recent advance. Medtronic Receives a Hold from Piper Sandler
• Negative Sentiment: Tariffs, inflation and unfavorable currency movements could pressure Medtronic’s margins. ETFs also reportedly sold $222.5 million of MDT shares on October 13, adding a potential short-term technical headwind. Is it Apt to Retain Medtronic Stock in Your Portfolio Now?

Insider Buying and Selling at Medtronic

In other news, EVP Michael Marinaro sold 10,420 shares of the company's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the sale, the executive vice president owned 105,916 shares of the company's stock, valued at approximately $10,167,936. This represents a 8.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the transaction, the chief executive officer directly owned 277,866 shares in the company, valued at approximately $26,397,270. This represents a 15.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,903 shares of company stock worth $5,889,203 over the last ninety days. Insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MDT. Wells Fargo & Company increased their price objective on Medtronic from $102.00 to $104.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 2nd. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $92.00 price objective on shares of Medtronic in a research note on Thursday, September 3rd. Robert W. Baird boosted their target price on Medtronic from $91.00 to $100.00 and gave the stock a "neutral" rating in a research report on Wednesday, September 2nd. Evercore set a $105.00 target price on Medtronic in a research note on Monday, July 6th. Finally, Bank of America raised their price target on Medtronic from $95.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, September 2nd. Seventeen equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $102.88.

Medtronic Trading Up 0.0%

NYSE MDT opened at $94.79 on Monday. The stock's 50-day simple moving average is $91.03 and its two-hundred day simple moving average is $85.01. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $121.25 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 2.16 and a beta of 0.55.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the previous year, the company posted $1.26 earnings per share. The company's revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Research analysts forecast that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were given a $0.72 dividend. The ex-dividend date was Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.0%. Medtronic's payout ratio is presently 70.94%.

Medtronic Company Profile

Medtronic plc NYSE: MDT is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company's offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.